News

Rebiotix has announced that it has completed enrollment of a phase 3 clinical trial for RBX2660.

Treatment with bezlotoxumab resulted in a statistically significant reduction of recurrent C diff in cancer patients, according to a new study.

February 7th is commemorated each year to highlight the impact that HIV and AIDS has on the black or African American population in the United States.

The first strain of influenza virus a person is exposed to in early childhood impacts their ability to fight flu for life. The phenomenon is known as antigenic imprinting.

The US Department of Health and Human Services announced that it is expanding an existing collaboration with Regeneron Pharmaceuticals in order to pursue a treatment for the 2019 novel coronavirus.

HIV-2 infections remain rare in the United States, but the CDC continues to recommend an HIV-1/HIV-2 differentiation test as a second step in testing.

An article concludes that there has been human-to-human transmission among close contacts since the middle of December 2019.

NIAID and partner organizations have discontinued HIV vaccination in a South Africa based experimental trial.

Gilead Sciences is collaborating with Chinese, US, and global health officials in order to investigate the safety and efficacy of their investigational antiviral compound remdesivir against the novel coronavirus.

There have been more than 19 million cases of influenza recorded in the United States over the 2019-20 flu season.

A study and commentary in The Lancet highlight unique challenges posed by controlled-release drugs.

In Medicaid data spanning a decade, more than a quarter of prescriptions were not associated with a clinician visit.

The US Food and Drug Administration has authorized the use of a new diagnostic for 2019 novel coronavirus.

Multiple blood cultures with appropriate volume can improve diagnosis and treatment of children with suspected sepsis or serious bacterial infection, according to a study at Children’s Hospital Colorado.

A retrospective study evaluated patients with cUTIs who received an outpatient prescription for multiple doses of fosfomycin between July 1999 and June 2018.

New research finds a small fraction of group A streptococcus strains are showing mutations that could lead to lower antibiotic susceptibility, and possibly someday resistance.

The US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices has released the 2020 Recommended Immunization Schedule for adults.

A new study provides evidence that more needs to be done to meet the needs of children in rural Zimbabwe who are exposed to HIV.

Regardless of HIV status, frailty was a strong predictor for mortality and comorbidity for middle-aged adults.

Minimal monitoring of patients receiving sofosbuvir-based therapy for hepatitis C virus resulted in equal cure rates at less cost than standard monitoring, a new study found.

The US Food and Drug Administration has approved Audenz, an adjuvanted influenza A H5N1 monovalent vaccine.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of January 26, 2020.

We’ve compiled a list of recalls issued by the US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) from this past week:

Alex Azar has declared a public health emergency in the United States in response to the 2019 novel coronavirus but says the risk to Americans remains low.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases will test the safety and effectiveness of monoclonal antibody CIS43LS used as prophylaxis against malaria.

Through the platform providers, consumers, and procurers will have access to full prescribing inserts and FDA-reviewed product labeling which will provide additional important information to patients and providers.

As January comes to an end, we’re looking back at important infectious disease news from the past month.

Newer, more effective antivirals mean hearts from donors with HCV are a viable option for transplantation. Rising opioid-related deaths means there are more of these donors available.

The CDC has also announced the first confirmed non-travel associated case of novel coronavirus in the United States.